Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY: CYBN )

10.03 -0.16 (-1.57%)
Official Closing Price Updated: 8:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cybin Inc. Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Psychedelic Stock Gainers And Losers From January 10, 2023
Via Benzinga
Where Are Psychedelics Headed In 2023? These Two Heavy Hitters Share Their Plans
It’s the beginning of 2023 and psychedelics companies are updating the public on their developmental and clinical progress as well as their selected milestones for the year. 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 9, 2023
Via Benzinga
ATAI Life Sciences, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 5, 2023
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 2, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From December 29, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 28, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From January 3, 2023
Via Benzinga
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
What a year for psychedelics! 
Via Benzinga
6 Largest Psychedelic Drug Stocks Were -20% In December
The Psychedelic Drug Stocks Index, which tracks the six largest psychedelic stocks researching the treatment of mental illnesses based on the use of one or more psychedelic substances, continued to... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From December 30, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 27, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 26, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 23, 2022
Via Benzinga
Cybin, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
Largest Psychedelic Stocks -7.6% This Week; Now -21.7% This Month
Highlighting the performance of the six stocks in our Psychedelic Drug Stocks Index, which are researching the treatment of mental illnesses using 10 different psychedelic substances. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From December 21, 2022
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From December 19, 2022
Via Benzinga
Major Psychedelic Drug Stocks Down Another 7% This Week; Now Down 54% YTD
The 6 largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances are down again this week. 
Via Talk Markets
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From December 14, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 13, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From December 12, 2022
Via Benzinga
Cannabis Category Performances Ranged From -5.1% To -35.3% Last Week
The 5 categories in the cannabis sector perform quite differently from week to week and last week was no exception. 
Via Talk Markets
Major Psychedelic Drug Stocks DOWN 9% Last Week; Now Down 51% YTD
Today's article highlights the performance of the largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.